BRIEF published on 05/26/2026 at 19:05, 14 days 6 hours ago MaaT Pharma Activity and Results Update for Q1 2026 Treasury MaaT Pharma Q1 2026 Results Xervyteg® CHAMP
BRIEF published on 05/26/2026 at 19:05, 14 days 6 hours ago MaaT Pharma Faces Challenges in Q1 2026 MaaT Pharma Early Access Program Q1 2026 Financial Results EMA Marketing Challenges Clinical Trials Update
PRESS RELEASE published on 05/26/2026 at 19:00, 14 days 6 hours ago Inside Information / Other news releases MaaT Pharma provides a business update and reports financial results for the first quarter of 2026, highlighting regulatory activities and cash position. Lyon, France Financial Results Business Update Cash Position MaaT Pharma Regulatory Activities
BRIEF published on 05/20/2026 at 20:50, 20 days 4 hours ago MAAT Pharma Faces Setback in Authorization for MaaT013 Biotech MaaT Pharma EMA MaaT013 AGvHD
PRESS RELEASE published on 05/20/2026 at 20:45, 20 days 4 hours ago Inside Information / Other news releases MaaT Pharma receives a 'negative trend' opinion from CHMP for their Marketing Authorization Application of MaaT013 (Xervyteg) in acute Graft-versus-Host Disease treatment. Company plans re-examination procedure MaaT Pharma CHMP Marketing Authorization Negative Trend Re-examination
BRIEF published on 04/21/2026 at 15:14, 1 month 18 days ago MaaT Pharma SACA Maintains Buy Rating with Stable Financial Outlook Financial Performance BUY Rating Pipeline Development MaaT Pharma Investment Case
PRESS RELEASE published on 04/21/2026 at 15:09, 1 month 18 days ago Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research reaffirms Buy rating for MaaT Pharma SACA with a target price of €17 following FY25 results and pipeline update. No changes to core investment case First Berlin Equity Research BUY Rating MaaT Pharma SACA FY25 Results €17 Target Price
BRIEF published on 04/01/2026 at 07:35, 2 months 8 days ago MaaT Pharma Presents CHRONOS Study Results on Third-Line Acute GvHD MaaT Pharma Regulatory Review CHRONOS Study Acute GvHD Third-line Therapy
BRIEF published on 04/01/2026 at 07:35, 2 months 8 days ago MaaT Pharma publishes data on aGvH in "Bone Marrow Transplantation" MaaT Pharma EMA AGvH Xervyteg® CHRONOS
PRESS RELEASE published on 04/01/2026 at 07:30, 2 months 8 days ago Inside Information / Other news releases MaaT Pharma announces publication of retrospective data from CHRONOS study in Bone Marrow Transplantation Journal, presenting real-world outcomes of third-line systemic treatments for GI-aGvHD patients MaaT Pharma GI-aGvHD CHRONOS Study Retrospective Data Bone Marrow Transplantation
Published on 06/10/2026 at 00:00, 1 hour 40 minutes ago Onco-Innovations Announces Initiation of API Process Development and Intermediate Scale-Up Program for its Proprietary PNKP Inhibitor Technology
Published on 06/09/2026 at 23:00, 2 hours 40 minutes ago NXT Energy Solutions Inc. Announces Results of Annual Meeting of Shareholders
Published on 06/09/2026 at 22:30, 3 hours 10 minutes ago Gamma Resources Announces Receipt of $604,500 from Warrant Exercises
Published on 06/09/2026 at 21:45, 3 hours 55 minutes ago Northfield Announces Change of Corporate Name to Juno International Corporation
Published on 06/09/2026 at 15:00, 10 hours 40 minutes ago Worksport Ltd. Reports Additional $50,000 CEO Insider Stock Acquisition, Reinforcing Confidence in Long-Term Value Creation
Published on 06/09/2026 at 22:55, 2 hours 45 minutes ago JACOBS STEPS-UP AS 'OFFICIAL SPONSOR OF STAYING AWAKE' AS SCHEDULE REVEALS SUMMER MATCH TIMES WILL PUSH EUROPEAN FOOTBALL FANS TO THE LIMIT
Published on 06/09/2026 at 22:35, 3 hours 5 minutes ago Eurobattery Minerals publishes Annual Report 2025
Published on 06/09/2026 at 19:32, 6 hours 7 minutes ago 2CRSi SA: 2CRSi announces a €110 million sale of Godì Blackwell Ultra servers in Germany
Published on 06/09/2026 at 19:10, 6 hours 29 minutes ago The 2026 Global Energy Prize shortlist released
Published on 06/09/2026 at 19:10, 6 hours 29 minutes ago THE SULTANATE OF OMAN CONSOLIDATES ITS POSITION AS A STABLE DESTINATION FOR GLOBAL CAPITAL
Published on 06/09/2026 at 19:30, 6 hours 10 minutes ago MONTHLY INFORMATION CONCERNING THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES
Published on 06/09/2026 at 18:14, 7 hours 26 minutes ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/05/2026
Published on 06/09/2026 at 15:17, 10 hours 23 minutes ago Statement of transactions in own shares from June 1, 2026 to June 5, 2026
Published on 06/09/2026 at 10:37, 15 hours 3 minutes ago Guillemot Corporation S.A. | Weekly report share buyback from June 1 to June 5 2026
Published on 06/09/2026 at 07:00, 18 hours 40 minutes ago New strategic Milestone for Biophytis: Official Establishment of Its Joint Venture in Asia
